A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Diffuse Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 07 Dec 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017.
- 07 Dec 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2017.
- 17 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.